Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Jiangsu Chia Tai Tianqing Pharmaceutical Group discovers HBV caspid assembly inhibitors

Aug. 10, 2020

Arbutus Biopharma identifies new hepatitis B virus HBsAg secretion inhibitors

Aug. 10, 2020

FDA approves Lampit for the treatment of Chagas disease in children

Aug. 10, 2020

High-throughput fluorescence polarization screen identifies new viral fusion inhibitor, F-0045

Aug. 10, 2020

Phase II/III study of opaganib in patients with COVID-19 receives approval in Mexico

Aug. 7, 2020

First patient enrolled in phase IIb/III study of ifenprodil for treatment of COVID-19

Aug. 7, 2020

Structure-guided analysis unveils the mechanism of action of a dengue virus 2-specific inhibitor

Aug. 7, 2020

Supportive preclinical reported for PTX-COVID19-B vaccine candidate

Aug. 7, 2020

Phase II study of BioAegis' gelsolin for COVID-19 begins in Spain

Aug. 6, 2020

Revive finalizing details for phase III study of bucillamine in COVID-19

Aug. 6, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...